Latest News on GKOS

Financial News Based On Company


Advertisement
Advertisement

Form 4 Glaukos Corp: Thomas William Burns (Director, CHAIRMAN & CEO) For: 9 April

https://ca.investing.com/news/stock-market-news/form-4-glaukos-corp-thomas-william-burns-director-chairman--ceo-for-9-april-93CH-4971099
This article reports on a Form 4 filing for Glaukos Corp, indicating insider transaction details for Thomas William Burns, who holds the positions of Director, Chairman, and CEO. The filing is specifically for April 9th. The article is brief, serving mainly as an announcement of the SEC filing.

When stock units vested, Glaukos (GKOS) withheld 3,907 shares from CEO Thomas William Burns for taxes.

https://www.stocktitan.net/sec-filings/GKOS/form-4-glaukos-corp-insider-trading-activity-517066de0024.html
Glaukos Corporation (GKOS) withheld 3,907 shares of common stock from its Chairman & CEO, Thomas William Burns, for tax obligations. This action occurred on April 9, 2024, at a price of $87.61 per share, following the vesting and delivery of previously granted restricted stock units. As of the Form 4 filing, Burns beneficially owned 65,060 securities, including 48,673 unvested restricted stock units.

Glaukos CEO Thomas Burns Withholds 3,907 Shares for RSU Tax Obligations

https://kalkinemedia.com/us/news/announcements/glaukos-ceo-thomas-burns-withholds-3907-shares-for-rsu-tax-obligations
Thomas William Burns, Chairman and CEO of Glaukos Corp, withheld 3,907 common stock shares on April 9, 2024, to cover tax obligations stemming from the vesting of restricted stock units. This transaction, reported via a Form 4 filing on November 19, 2026, was exempt under Rule 16b-3. Following the withholding, Burns' beneficial ownership in Glaukos Corp (NYSE:GKOS) stands at 65,060 shares, including unvested RSUs.

Glaukos president & COO Joseph Gilliam sells $215,250 in stock

https://www.investing.com/news/insider-trading-news/glaukos-president--coo-joseph-gilliam-sells-215250-in-stock-93CH-5037459
Joseph E. Gilliam, President and COO of Glaukos Corp (NASDAQ:GKOS), sold 861 shares of company stock for $215,250 on November 16, 2026, after exercising options for an equivalent number of shares. The transactions were conducted under a Rule 10b5-1 trading plan. Despite the sale, Glaukos recently reported strong Q3 2026 financial results, surpassing analyst expectations and leading to increased price targets from several firms.

Form 4 Glaukos Corp: Joseph E. Gilliam (PRESIDENT & COO) For: 16 November

https://uk.investing.com/news/stock-market-news/form-4-glaukos-corp-joseph-e-gilliam-president--coo-for-16-november-93CH-4991978
This article reports on a Form 4 filing for Glaukos Corp, indicating an insider transaction by Joseph E. Gilliam, the President & COO, on November 16. The specific details of the transaction are not provided within the brief article content, but it signals an official report of changes in ownership for a company insider. The article also provides the stock symbol GKOS and its current performance.
Advertisement

GKOS: A $1 billion 2027 outlook pairs launch growth with expanding access and strong margin potential

https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:4681355:0-gkos-a-1-billion-2027-outlook-pairs-launch-growth-with-expanding-access-and-strong-margin-potential/
Glaukos Corporation (GKOS) anticipates achieving $1 billion in revenue by 2027, driven by expanding access to Epioxa and iDose, and growth in the keratoconus market. Management expects strong margins and plans continued investment in new launches and pipeline development. This outlook is based on a transcript from the Jefferies Global Healthcare Conference.

What Drove Glaukos Stock's 48% Rally Since the End of September?

https://www.tradingview.com/news/zacks:40817c3b2094b:0-what-drove-glaukos-stock-s-48-rally-since-the-end-of-september/
Glaukos (GKOS) stock has rallied 48% since September-end, primarily driven by stronger-than-expected third-quarter performance, which led to a significant increase in full-year sales guidance. Positive clinical developments for Epioxa and iDose TR, along with an expansion into the retinal pipeline, have further bolstered the company's growth outlook. The company is transitioning from a glaucoma-focused business to a broader ophthalmology platform, fueling investor confidence.

Form 4 Glaukos Corp: Joseph E. Gilliam (PRESIDENT & COO) For: 12 November By Investing.com

https://in.investing.com/news/stock-market-news/form-4-glaukos-corp-joseph-e-gilliam-president--coo-for-12-november-93CH-5708524
This article reports on a Form 4 filing for Glaukos Corp, indicating an insider transaction by Joseph E. Gilliam, the President & COO. The transaction occurred on November 12th. The article provides the title and date of the filing, without further details about the nature of the transaction.

Shared voting power covers 4.63 million Glaukos (GKOS) shares for Janus Henderson.

https://www.stocktitan.net/sec-filings/GKOS/schedule-13g-a-glaukos-corp-amended-passive-investment-disclosure-35a2e75dfa59.html
Janus Henderson Group Ltd. has reported a 7.9% beneficial ownership in Glaukos Corp (GKOS), amounting to 4,629,689 common shares, as of September 30, 2026. The filing indicates that Janus Henderson holds shared voting and dispositive power over all these shares, with no sole power. The rights to dividends and sale proceeds, however, belong to the Managed Portfolios, and Janus Henderson disclaims ownership associated with these rights.

Glaukos stock price target raised to $252 by BTIG on revenue outlook

https://www.investing.com/news/analyst-ratings/glaukos-stock-price-target-raised-to-252-by-btig-on-revenue-outlook-93CH-5028926
BTIG has raised its price target for Glaukos Corporation (NYSE:GKOS) to $252 from $234, maintaining a Buy rating, following the company's preliminary fiscal year 2027 revenue guidance of approximately $1 billion. This ambitious target surpasses prior consensus estimates and reflects significant growth from current revenues, driven by Epioxa performance, iDose ramp, and international momentum. Other firms like H.C. Wainwright, Piper Sandler, Needham, Mizuho, and Truist Securities also increased their price targets for Glaukos after its strong third-quarter 2026 financial results.
Advertisement

BTIG maintains Glaukos at Buy, raises price target to $252 from $234

https://www.tradingview.com/news/tradingview:4ff9a95a0e034:0-btig-maintains-glaukos-at-buy-raises-price-target-to-252-from-234/
BTIG has reiterated its "Buy" rating for Glaukos (GKOS) and increased its price target from $234 to $252, representing a 7.7% raise. This new price target suggests a 2.6% upside from Glaukos's closing price of $245.72 on November 13. This action follows several other analysts who also maintained "Buy" or "Overweight" ratings for Glaukos in late October, with price targets ranging from $226 to $255.

Should Strong Q3 Results Require Action From Glaukos (GKOS) Investors?

https://simplywall.st/stocks/us/healthcare/nyse-gkos/glaukos/news/should-strong-q3-results-require-action-from-glaukos-gkos-in
Glaukos (GKOS) recently reported strong Q3 results with increased sales guidance, driven by products like iDose TR and Epioxa. While demand is robust, the company's near-term success hinges on converting billed procedures into cash, particularly regarding reimbursement clarity for iDose TR and Epioxa. Analysts have raised fair value estimates, reflecting confidence in the traction of these products, though risks related to reimbursement and procedure volumes persist.

Form 144 GLAUKOS Corp For: 13 November By Investing.com

https://in.investing.com/news/stock-market-news/form-144-glaukos-corp-for-13-november-93CH-5702035
This article from Investing.com announces that a Form 144 has been filed for GLAUKOS Corp on November 13. It is a brief, one-sentence news item providing a factual update on a financial filing.

Form 144 GLAUKOS Corp For: 13 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-glaukos-corp-for-13-november-93CH-4955751
This article announces that Glaukos Corp. (GKOS) has filed a Form 144 on November 13, 2026. A Form 144 is a notice of the intent to sell restricted securities. The article provides the title of the filing and its publication date without further details on the content of the form.

(GKOS) Movement as an Input in Quant Signal Sets

https://news.stocktradersdaily.com/news_release/15/GKOS_Movement_as_an_Input_in_Quant_Signal_Sets_111126013602_1794422162.html
This article from Stock Traders Daily provides an AI-generated analysis of Glaukos Corporation (NASDAQ: GKOS), offering three distinct trading strategies for different risk profiles and holding periods. It highlights weak near-term sentiment but strong mid and long-term signals, alongside specific entry, target, and stop-loss levels for position, momentum breakout, and risk hedging strategies. The report also details support and resistance levels across various time horizons.
Advertisement

GKOS: Epioxa access is advancing; market expansion and payer execution will shape 2027 growth

https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:4558414:0-gkos-epioxa-access-is-advancing-market-expansion-and-payer-execution-will-shape-2027-growth/
Glaukos Corporation's (GKOS) Epioxa payer access has exceeded expectations, with future growth in 2027 dependent on patient access, awareness, and payer execution. The company's iDose product retains long-term support, and 2027 spending priorities will focus on launch expansion and pipeline investment, as highlighted at the Stifel 2026 Healthcare Conference.

Glaukos (GKOS) Jumped, What Is Behind The Fresh Attention?

https://simplywall.st/stocks/us/healthcare/nyse-gkos/glaukos/news/glaukos-gkos-jumped-what-is-behind-the-fresh-attention
Glaukos (GKOS) has seen a significant jump in investor attention due to a move to profitability in Q3 2026, raised sales guidance, and its reclassification from the S&P 600 to the S&P 400. While the stock has shown strong momentum, with share price returns of 35.44% over 30 days and 102.68% year-to-date, analysts at Simply Wall St suggest it may be 27% overvalued based on a fair value near $176.97 compared to its closing price of $224.41. The narrative highlights potential risks from increasing operating expenses that could limit cash flow improvement despite healthy top-line trends.

Learn Why The Bull Case For Glaukos Stock Could Change Following S&P 400 Inclusion

https://simplywall.st/stocks/us/healthcare/nyse-gkos/glaukos/news/learn-why-the-bull-case-for-glaukos-stock-could-change-follo
Glaukos (NYSE:GKOS) recently reported strong Q3 2026 results, including a return to profitability and raised full-year sales guidance, leading to its inclusion in the S&P 400. This index promotion has driven significant ETF inflows, altering the shareholder base. While the core risk around reimbursement remains, the raised sales outlook of US$775 million to US$785 million underscores the growing adoption of its products and frames future investor expectations for iDose TR and Epioxa.

Glaukos Shares November 2026 Investor Presentation, Citing 30% 2025 Growth

https://www.tradingview.com/news/tradingview:4629b9143e1a7:0-glaukos-shares-november-2026-investor-presentation-citing-30-2025-growth/
Glaukos (GKOS) released an investor presentation highlighting its growth, ophthalmic product portfolio, and pipeline, including a projected 30% topline growth in 2025. The presentation details 14 pipeline programs, 12 commercialized products, and recent FDA approvals for iDose TR re-administration and the commercial availability of Epioxa. The company also reported strong financials with $340 million in cash and equivalents and an 88% adjusted gross margin in Q3 2026.

Glaukos Corporation (GKOS) Seasonal Returns Chart

https://ca.finance.yahoo.com/quote/GKOS/seasonality/
The article provides a seasonal returns chart for Glaukos Corporation (GKOS), showing the average monthly price return from 2016 to 2026. It indicates the stock's current price and its performance during market close and after hours on November 6. The content is primarily a data presentation, devoid of narrative analysis.
Advertisement

Glaukos and RevOpsis partner on retina tri-specific therapy development, commercialization

https://glance.eyesoneyecare.com/stories/2026-11-06/glaukos-and-revopsis-partner-on-retina-tri-specific-therapy-development-commercialization/
Glaukos Corporation and RevOpsis Therapeutics have announced an exclusive license agreement to develop and commercialize RO-104, a novel tri-specific biologic, for retinal diseases like wet age-related macular degeneration. The partnership leverages RevOpsis' proprietary RevMod Platform, which allows for the creation of multispecific antibody biologics targeting multiple pathways in complex ophthalmic diseases. Glaukos will gain rights to RO-104 and the RevMod platform for up to four additional retinal biologic candidates.

Glaukos director Gilbert Kliman sells $632,500 in shares

https://www.investing.com/news/insider-trading-news/glaukos-director-gilbert-kliman-sells-632500-in-shares-93CH-5006224
Gilbert H. Kliman, a director at Glaukos Corporation (NASDAQ:GKOS), sold 2,500 shares for $632,500 on November 4, 2026, after acquiring an equal number through stock option exercises. This transaction follows a 169% surge in Glaukos shares over the past year, though the current trading price is below the sale price. The company recently reported strong Q3 2026 financial results with significant revenue growth and raised 2026 guidance.

Form 4 Glaukos Corp: Gilbert H. Kliman (Director) For: 4 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-4-glaukos-corp-gilbert-h-kliman-director-for-4-november-93CH-4936939
This article reports on a Form 4 filing for Glaukos Corp (GKOS) concerning director Gilbert H. Kliman, noting a transaction on November 4. The brief piece indicates that Glaukos Corp's stock experienced a significant drop of 10.83%.

Glaukos Director Sold Shares Worth Over $632K

https://www.tradingview.com/news/tradingview:7cbdfeb7a8dfe:0-glaukos-director-sold-shares-worth-over-632k/
Glaukos Director Gilbert H. Kliman sold 2,500 shares of Glaukos common stock at $253 per share, totaling $632,500. Following this transaction, Kliman directly owns 37,406 shares of the company. This information is based on an SEC Form 4 filing.

Form 144 GLAUKOS Corp For: 4 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-glaukos-corp-for-4-november-93CH-4931545
This article from Investing.com announces the filing of Form 144 for Glaukos Corp on November 4, 2026. Form 144 typically indicates an insider's intent to sell restricted securities. The brief notice highlights Glaukos Corp's stock symbol GKOS, which showed a 5.86% increase at the time of publication.
Advertisement

Is Glaukos (GKOS) Still Cheap After Record Sales And Profit?

https://sg.finance.yahoo.com/news/glaukos-gkos-still-cheap-record-151010217.html
Glaukos (GKOS) has seen its share price climb significantly in 2026 due to record sales, index moves, and a shift to profitability, reaching US$233.04. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued, projecting future cash flows that significantly exceed its current price, supported by strong Q3 results and therapies like iDose TR and Epioxa. However, differing narratives exist, with some analysts viewing it as undervalued and others seeing it as overvalued due to reimbursement pressure.

A development chief exercises options at $55 and sells Glaukos (GKOS) shares.

https://www.stocktitan.net/sec-filings/GKOS/form-4-glaukos-corp-insider-trading-activity-5a8c29607902.html
Tomas Navratil, Chief Development Officer at Glaukos Corp (GKOS), exercised options to acquire 4,181 shares at $55 and 8,788 shares at $85.94 on October 30, 2026. On the same day, he sold 44,436 shares in four transactions, with weighted-average prices ranging from $237.54 to $240.52. The options vest over four years, with 25% on the first anniversary and the remainder in monthly installments.

Glaukos CDO Tomas Navratil sells $10.6 million in company shares By Investing.com

https://za.investing.com/news/stock-market-news/glaukos-cdo-tomas-navratil-sells-106-million-in-company-shares-93CH-4548073
Tomas Navratil, Chief Development Officer at Glaukos Corp (NASDAQ:GKOS), sold approximately $10.6 million in company shares on October 30, 2026, following the exercise of stock options. The sale occurred while GKOS stock was near its 52-week high, with InvestingPro analysis suggesting it is overvalued. Despite this, the company recently reported strong Q3 2026 financial results, exceeding analyst expectations and leading to increased revenue guidance for 2026 and 2027.

Glaukos (GKOS) Joins The S&P 400, Is It Overvalued At Current Levels?

https://sg.finance.yahoo.com/news/glaukos-gkos-joins-p-400-031548646.html
Glaukos (GKOS) has moved from the S&P 600 to the S&P 400, leading to a significant short-term stock price increase. While one valuation model suggests the stock is 17% overvalued at $233.04 compared to a fair value of $199.31, another discounted cash flow analysis indicates it might be undervalued with a future cash flow value of $367.63. Investors are advised to consider both perspectives, along with potential risks and opportunities, before making investment decisions.

Form 4 Glaukos Corp: Aimee S. Weisner (Director) For: 30 October

https://uk.investing.com/news/stock-market-news/form-4-glaukos-corp-aimee-s-weisner-director-for-30-october-93CH-4954529
This article reports on a Form 4 filing for Glaukos Corp, indicating an insider transaction by Aimee S. Weisner, a director of the company, on October 30. The filing, published on November 4, 2026, provides details about this specific insider activity for the company, whose stock symbol is GKOS.
Advertisement

Glaukos Chief Development Officer Sold Shares Worth Over $10M

https://www.tradingview.com/news/tradingview:6b52f198ea2ed:0-glaukos-chief-development-officer-sold-shares-worth-over-10m/
Tomas Navratil, Chief Development Officer of Glaukos, sold 44,436 shares of common stock on October 30, 2026, across four transactions, totaling $10,618,979. The shares were sold at weighted average prices between $237.54 and $240.52. Following these sales, Navratil directly owns 37,328 shares, which includes unvested restricted stock units.

Glaukos (GKOS) executive Navratil sold 44,436 shares for $10.6M at an average $238.97

https://quantisnow.com/insight/chief-development-officer-navratil-tomas-exercised-12969-shares-at-a-6770855
Tomas Navratil, Chief Development Officer at Glaukos (GKOS), sold 44,436 shares for $10.6 million at an average price of $238.97. Concurrently, Navratil acquired 12,969 shares at an average of $75.97, leaving a direct holding of 37,328 shares after these transactions on October 30, 2026. These insider transactions were reported via a Form 4 filing.

Glaukos CDO Tomas Navratil sells $10.6 million in company shares

https://www.investing.com/news/insider-trading-news/glaukos-cdo-tomas-navratil-sells-106-million-in-company-shares-93CH-4997199
Tomas Navratil, Chief Development Officer at GLAUKOS Corp, sold approximately $10.6 million worth of company shares on October 30, 2026, while also exercising stock options to acquire shares. These transactions occurred as GKOS stock traded near its 52-week high, with the company recently reporting strong third-quarter 2026 financial results and increased revenue guidance. Analysts have raised price targets for Glaukos following these positive developments.

Stock grants trigger tax withholding for Glaukos (GKOS) development chief: 755 shares withheld.

https://www.stocktitan.net/sec-filings/GKOS/form-4-glaukos-corp-insider-trading-activity-ffd64cf931f1.html
Glaukos Corp's chief development officer, Tomas Navratil, had 755 common shares withheld on April 9, 2024, to cover tax obligations arising from the vesting of restricted stock units. These transactions involved 495 shares at $87.61 and 260 shares at $93.23, corresponding to units granted in 2021 and 2022, respectively. Following these transactions, Navratil directly holds 68,536 common shares.

Glaukos (GKOS) executive Navratil sold 44,436 shares for $10.6M at an average $238.97

https://www.quantisnow.com/insight/chief-development-officer-navratil-tomas-exercised-12969-shares-at-a-6770855
Tomas Navratil, Chief Development Officer at Glaukos Corporation (GKOS), reported selling 44,436 shares for $10.6 million at an average price of $238.97, while also acquiring 12,969 shares at an average of $75.97 on October 30, 2026. Following these transactions, Navratil directly holds 37,328 shares. The filing details multiple trades and the exercise of stock options, leaving no direct stock options held after the transactions.
Advertisement

Conferences in New York, London and Miami are on Glaukos management's schedule.

https://www.stocktitan.net/news/GKOS/glaukos-announces-participation-in-upcoming-investor-36k47f60rw54.html
Glaukos (GKOS) announced its management will participate in four investor conferences in November and December 2026. These include the Stifel Healthcare Conference, Jefferies Global Healthcare Conference, Piper Sandler Annual Healthcare Conference, and Citi Global Healthcare Conference, taking place in New York City, London, and Miami. Webcasts for these events will be available on the company's investor relations website.

Glaukos Corporation Stock 12‑Month Price Target Raised to $235.46, Implies 30% Upside

https://www.tradingview.com/news/tradingview:b298a4e80a88f:0-glaukos-corporation-stock-12-month-price-target-raised-to-235-46-implies-30-upside/
Thirteen analysts have raised Glaukos Corporation's average 12-month price target from $199.31 to $235.46, with forecasts ranging from $172 to $270 per share. This new target implies a potential upside of approximately 30% based on the Oct. 28 closing price. The consensus rating for the stock remains a "Buy" from 15 covering analysts.

Piper Sandler raises Glaukos stock price target on Epioxa strength

https://www.investing.com/news/analyst-ratings/piper-sandler-raises-glaukos-stock-price-target-on-epioxa-strength-93CH-4984262
Piper Sandler has increased its price target for Glaukos Corporation (NYSE:GKOS) to $240 from $195, maintaining an Overweight rating, following strong third-quarter results. The company's revenue of $211.0 million significantly surpassed estimates, driven by impressive performance in its iDose and corneal health segments, particularly with the Epioxa launch. Glaukos also raised its fiscal 2026 revenue guidance and provided strong preliminary guidance for fiscal 2027, indicating substantial upside potential.

Top 5 Stocks for October 29 Pre-Market: Earnings Reaction Gainers Led by Glaukos Corporation (NYSE:GKOS) at 15.75%

https://kalkine.com.au/news/corporate-earnings/top-5-stocks-for-october-29-pre-market-earnings-reaction-gainers-led-by-glaukos-corporation-nysegkos-at-1575
This article highlights the top five pre-market stock gainers on October 29, 2026, driven by their third-quarter earnings reactions. Glaukos Corporation (NYSE:GKOS) led with a 15.75% gain due to raised guidance, followed by Teladoc Health (NYSE:TDOC), Carvana (NYSE:CVNA), Chipotle Mexican Grill (NYSE:CMG), and eBay (NASDAQ:EBAY). The article details the specific catalysts for each company's pre-market advance, such as revenue outlook increases, narrower losses, unit growth, or maintained guidance.

Glaukos Corporation (GKOS) PT Raised to $251 at Needham

https://www.streetinsider.com/Analyst+Comments/Glaukos+Corporation+%28GKOS%29+PT+Raised+to+%24251+at+Needham/27251894.html
Needham analyst David Saxon raised the price target for Glaukos Corporation (NYSE: GKOS) to $251.00 from $201.00, reiterating a Buy rating. This adjustment follows GKOS' strong Q326 revenue beat, driven by Epioxa, which led to positive profitability and increased 2026 and 2027 revenue guidance. The analyst anticipates continued growth due to an expanding Epioxa site of care network and improved market access.
Advertisement

Glaukos Corp stock hits all-time high at 210.0 USD

https://www.investing.com/news/company-news/glaukos-corp-stock-hits-alltime-high-at-2100-usd-93CH-4983970
Glaukos Corp's stock has reached an all-time high of $210.0, driven by strong investor confidence and significant revenue growth, despite analysts not anticipating profitability this year. The company's third-quarter results surpassed expectations, with robust demand for its glaucoma and corneal products, leading several analysts to raise their price targets. Glaukos has also increased its 2026 revenue guidance and provided optimistic 2027 guidance, reflecting a strong outlook for future growth.

Glaukos Corp earnings beat by $0.57, revenue topped estimates

https://www.investing.com/news/earnings/glaukos-corp-earnings-beat-by-057-revenue-topped-estimates-4980688
Glaukos Corp reported a significant beat on its third-quarter earnings per share, coming in at $0.47 against an analyst estimate of -$0.10. The company also surpassed revenue expectations, bringing in $211.03 million compared to a consensus estimate of $168.03 million. Furthermore, Glaukos Corp provided strong FY 2026 revenue guidance, exceeding analyst consensus.

Glaukos Corporation (GKOS) Tops Q3 EPS by 57c; Offers Guidance

https://www.streetinsider.com/Earnings/Glaukos+Corporation+%28GKOS%29+Tops+Q3+EPS+by+57c%3B+Offers+Guidance/27249514.html
Glaukos Corporation (GKOS) reported strong Q3 earnings, surpassing analyst estimates with an EPS of $0.47, significantly higher than the anticipated ($0.10). The company also exceeded revenue expectations, bringing in $211.03 million against a consensus of $168.03 million. Furthermore, Glaukos provided an optimistic FY2026 revenue guidance of $775-785 million, well above the consensus forecast of $691.7 million.

Glaukos: Q3 Earnings Snapshot

https://www.ktvb.com/article/syndication/associatedpress/glaukos-q3-earnings-snapshot/616-85d0cc9d-503e-4874-a60d-0f99da36c2da
Glaukos Corp. (GKOS) reported strong third-quarter results, with net income reaching $2 million, or 3 cents per share. Adjusted earnings of 47 cents per share significantly surpassed Wall Street's expectation of a 12-cent loss. The glaucoma treatments developer also exceeded revenue forecasts, posting $211 million against an expected $168.8 million, and projects full-year revenue between $775 million and $785 million.

Glaukos (GKOS) Wins Epioxa J Code As Investors Ask If The Stock Is Fully Valued

https://simplywall.st/stocks/us/healthcare/nyse-gkos/glaukos/news/glaukos-gkos-wins-epioxa-j-code-as-investors-ask-if-the-stoc
Glaukos (GKOS) recently secured a permanent J-code for its Epioxa therapy, driving its share price up by 61.56% year-to-date and 136.36% over the last year. While the stock is currently trading near record levels, some investors consider it 4% overvalued at $178.88 compared to a fair value estimate of $172.00, due to concerns about increasing operating expenses. However, a discounted cash flow (DCF) model suggests the stock might be undervalued by 33.4%, with a fair value of $268.77 per share.
Advertisement

Glaukos Corporation (GKOS) Stock forecasts

https://uk.finance.yahoo.com/research/reports/ARGUS_5865_QuantitativeReport_1792540800000
Argus has raised its target price for Glaukos Corporation (GKOS) to $182.00. Glaukos Corp is an ophthalmic pharmaceutical and medical technology company specializing in treatments for glaucoma, corneal disorders, and retinal diseases. The current stock price for GKOS is $178.88.

Glaukos Corporation Estimates – NYSE:GKOS

https://www.tradingview.com/symbols/NYSE-GKOS/financials-estimates/?category=balance_sheet
This page provides an overview of Glaukos Corporation (NYSE: GKOS) financials, including actual results and analyst estimates across income statements, balance sheets, cash flow statements, and valuation metrics. Users can explore reported financial data and compare it with average, high, and low estimates, as well as visualize trends over time. The platform emphasizes that the information is not investment advice and encourages users to conduct their own research.

Does RevOpsis Retina Deal Change The Bull Case For Glaukos (GKOS)?

https://simplywall.st/stocks/us/healthcare/nyse-gkos/glaukos/news/does-revopsis-retina-deal-change-the-bull-case-for-glaukos-g
Glaukos Corporation has expanded into retinal disease treatments through an exclusive license agreement with RevOpsis Therapeutics, aiming to develop and commercialize biologic candidates for conditions like nAMD and DME. This move signals a shift beyond Glaukos' traditional glaucoma devices and iDose TR into drug-based therapies, potentially reshaping its long-term R&D priorities. While near-term focus remains on glaucoma execution and iDose TR adoption, the RevOpsis deal introduces a new growth engine, with analysts offering varied perspectives on its impact on future revenue and earnings.

GKOS Q3'26 Earnings: revenue estimate is 168.04M USD

https://www.tradingview.com/news/tradingview:b41f409c93481:0-gkos-q3-26-earnings-revenue-estimate-is-168-04m-usd/
Glaukos Corporation (GKOS) is projected to announce its Q3'26 earnings on October 28, 2026, after market close, with an expected disclosure at 4:05 PM ET (8:05 PM UTC). Analysts estimate the company's Q3'26 revenue to be $168.04 million and EPS at ($0.10). The report also provides a comparison of past reported and estimated revenues and EPS, highlighting revenue and EPS surprises.

Glaukos Corporation (GKOS) Stock Price, News & Analysis

https://www.stocktitan.net/overview/GKOS/
This article provides an overview of Glaukos Corporation (GKOS), an ophthalmic pharmaceutical and medical technology company specializing in treatments for glaucoma, corneal disorders, and retinal diseases. It details Glaukos's key products like iStent, iDose TR, Photrexa, and Epioxa, emphasizing their "dropless" and long-duration treatment approaches. The report also covers recent news, SEC filings, financial highlights from FY2025, and upcoming corporate events, alongside stock performance metrics.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement